comparemela.com

Latest Breaking News On - Tang renhong - Page 1 : comparemela.com

First Prescription for COSELA® (trilaciclib) Issued in China

/PRNewswire/ Simcere Pharmaceutical Group Limited (2096.HK) ("Simcere"), an innovative global biopharmaceutical company, and G1 Therapeutics, Inc., (Nasdaq:.

United statesTang renhongJack baileySimcere pharmaceutical groupPrnewswire simcere pharmaceutical groupTherapeutics incResearch triangle parkNational comprehensive cancer networkChinese society of clinical oncologyJilin cancer hospitalPharmaceutical group limitedChief executive officerExecutive directorComprehensive cancerClinical practice guidelinesClinical oncology

PHASE II/III CLINICAL TRIAL OF SIMCERE S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT

/PRNewswire/ Simcere Pharmaceutical Group (2096.HK) announced today that, XIANNUOXIN (SIM0417), an anti-SARS-CoV-2 drug candidate jointly developed by.

Wang chenTang renhongNational centerSimcere pharmaceutical groupNational medical products administrationChinese academy of medical sciencesShanghai institute of materia medicaWuhan institute of virologyChinese academy of sciencesShanghai instituteMateria medicaWuhan instituteChinese academyNew drug applicationAcademician wang chenMedical sciences

Simcere: SIMCERE PHARMA (HK 2096) to host 2022 R&D Day

HONG KONG, April 7, 2022 /PRNewswire/ SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pharmaceutical company with a mission of "providing today's patients with medicines of the future"

Ekevin oliverRen jinshengJason baoDanny chenBijoyesh mookerjeeSimcere pharmaceutical groupInnovative drug developmentNational key laboratory of translational medicineZhou gaoboTang renhongPharmaceutical groupNational key laboratoryTranslational medicineInnovative drug

vimarsana © 2020. All Rights Reserved.